SCHEMBL16747845

SCHEMBL16747845

Cc1nc2ccc(F)cn2c1-c1cncc(Nc2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.43
▸ SLC2A1 P11166 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TP53 P04637 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ APP P05067 1/20 0.39
▸ IDH2 P48735 2/20 0.39
▸ KIF11 P52732 1/20 0.39
▸ AURKA O14965 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CTSC P53634 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ CYP11B1 P15538 1/20 0.37
▸ CYP11B2 P19099 1/20 0.37
▸ MPO P05164 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739698 0.89 KDR (0.46) SLC2A1KMT2AHSD17B10TP53MAPT
SCHEMBL16747837 0.88 KCNH2 (0.42) CYP11B1CYP11B2
SCHEMBL16740044 0.86 KDR (0.48) GSK3B
SCHEMBL16739855 0.86 KDR (0.48) KMT2ATP53MAPTHTTCYP11B1
SCHEMBL16740170 0.86 CDK2 (0.42) KMT2ATP53MAPTHTTSMN1; SMN2
SCHEMBL16740204 0.85 CYP11B2 (0.39) CYP11B1CYP11B2
SCHEMBL16740174 0.85 KDR (0.39) SLC2A1MAPTHTTSMN1; SMN2GSK3B
SCHEMBL16739829 0.83 BRAF (0.42) KMT2ATP53MAPTHTTSMN1; SMN2
SCHEMBL16739953 0.80 CDK2 (0.43) KMT2ATP53MAPTSMN1; SMN2CYP11B1
SCHEMBL16747839 0.80 KCNH2 (0.47) THRBCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 — — US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B THRB 1849/4885SLC2A1 3216/4885KMT2A 132/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B THRB 1849/4885SLC2A1 3216/4885KMT2A 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback